These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 33949040)

  • 41. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
    Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
    Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Linking miRNA regulation to BCR-ABL expression: the next dimension.
    Faber J; Gregory RI; Armstrong SA
    Cancer Cell; 2008 Jun; 13(6):467-9. PubMed ID: 18538729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ku70 suppresses alternative end joining in G1-arrested progenitor B cells.
    Liang Z; Kumar V; Le Bouteiller M; Zurita J; Kenrick J; Lin SG; Lou J; Hu J; Ye AY; Boboila C; Alt FW; Frock RL
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. bcr/abl mRNA in leukemic blasts of an unusual patient with acute lymphoblastic leukemia followed after 5-year remission by chronic myelogenous leukemia in blast crisis.
    Fujie H; Tsuchiya S; Morita S; Itano M; Yambe T; Ohasi Y; Minegishi N; Minegishi M; Satou T; Konno T
    Leukemia; 1994 Sep; 8(9):1592-5. PubMed ID: 8090037
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
    Borges CS; Ferreira AF; Almeida VH; Gomes FG; Berzoti-Coelho MG; Cacemiro MDC; Nunes NS; Figueiredo-Pontes LL; Simões BP; Castro FA; Monteiro RQ
    Exp Hematol; 2018 Oct; 66():50-62. PubMed ID: 30076949
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.
    Hiroki H; Ishii Y; Piao J; Namikawa Y; Masutani M; Honda H; Akahane K; Inukai T; Morio T; Takagi M
    Sci Rep; 2023 May; 13(1):7588. PubMed ID: 37165001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of Dok-1 and Dok-2 in leukemia suppression.
    Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
    J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reactive oxygen species in BCR-ABL1-expressing cells - relevance to chronic myeloid leukemia.
    Antoszewska-Smith J; Pawlowska E; Blasiak J
    Acta Biochim Pol; 2017; 64(1):1-10. PubMed ID: 27904889
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
    Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
    Quintás-Cardama A; Cortes J
    Blood; 2009 Feb; 113(8):1619-30. PubMed ID: 18827185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
    Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D
    Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
    Nakahara F; Sakata-Yanagimoto M; Komeno Y; Kato N; Uchida T; Haraguchi K; Kumano K; Harada Y; Harada H; Kitaura J; Ogawa S; Kurokawa M; Kitamura T; Chiba S
    Blood; 2010 Apr; 115(14):2872-81. PubMed ID: 19861684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
    Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
    Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monitoring of childhood ALL using
    Hovorkova L; Zaliova M; Venn NC; Bleckmann K; Trkova M; Potuckova E; Vaskova M; Linhartova J; Machova Polakova K; Fronkova E; Muskovic W; Giles JE; Shaw PJ; Cario G; Sutton R; Stary J; Trka J; Zuna J
    Blood; 2017 May; 129(20):2771-2781. PubMed ID: 28331056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathway.
    Liu X; Mai H; Jiang H; Xing Z; Peng D; Kong Y; Zhu C; Chen Y
    BMC Cancer; 2019 Jul; 19(1):679. PubMed ID: 31291942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.